Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:administered_via |
oral route
|
| gptkbp:approvedBy |
gptkb:FDA
2020 (USA) |
| gptkbp:ATCCode |
P01CC02
|
| gptkbp:CASNumber |
23256-30-6
|
| gptkbp:chemicalClass |
nitrofuran
|
| gptkbp:contraindication |
pregnancy
severe liver disease |
| gptkbp:developedBy |
gptkb:Bayer
|
| gptkbp:discoveredBy |
1965
|
| gptkbp:eliminationHalfLife |
2–6 hours
|
| gptkbp:has_trade_name |
gptkb:Lampit
|
| gptkbp:hasMolecularFormula |
C10H9N3O5
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nifurtimoxum
|
| gptkbp:IUPACName |
(1-[(5-nitro-2-furyl)methylene]amino)-3-methyl-2-butanone
|
| gptkbp:mechanismOfAction |
produces nitro-anion radicals toxic to parasites
|
| gptkbp:meltingPoint |
187–190 °C
|
| gptkbp:sideEffect |
nausea
vomiting abdominal pain weight loss peripheral neuropathy |
| gptkbp:usedFor |
gptkb:African_trypanosomiasis
gptkb:Chagas_disease |
| gptkbp:bfsParent |
gptkb:nifurtimox
|
| gptkbp:bfsLayer |
7
|